RECOMMANDATIONS POUR ÉVALUATION DU RISQUE

Les recommandations¹ canadiennes en matière de soins de soutien pour le traitement de la neutropénie comprennent un algorithme pour l’utilisation du G-CSF qui associe les recommandations de l’ASCO (American Society of Clinical Oncology)² et celles de l’EORTC (European Organisation for Research and Treatment of Cancer).³

Références :

1. Kouroukis C, Chia S, Cripps C, et al. Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol 2008;15:9-23.
2. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
3. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53.